128 related articles for article (PubMed ID: 22351694)
1. MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1.
Birner P; Beer A; Vinatzer U; Stary S; Höftberger R; Nirtl N; Wrba F; Streubel B; Schoppmann SF
Clin Cancer Res; 2012 Apr; 18(7):1879-87. PubMed ID: 22351694
[TBL] [Abstract][Full Text] [Related]
2. Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.
Hayashi Y; Bardsley MR; Toyomasu Y; Milosavljevic S; Gajdos GB; Choi KM; Reid-Lombardo KM; Kendrick ML; Bingener-Casey J; Tang CM; Sicklick JK; Gibbons SJ; Farrugia G; Taguchi T; Gupta A; Rubin BP; Fletcher JA; Ramachandran A; Ordog T
Gastroenterology; 2015 Aug; 149(2):420-32.e16. PubMed ID: 25865047
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of CIC does not associate with overexpression of ETV1 or MAP kinase pathway activation in gastrointestinal stromal tumors.
Schoppmann SF; Ricken G; Ilhan-Mutlu A; Nirtl N; Streubel B; Preusser M; Birner P
Cancer Invest; 2014 Aug; 32(7):363-7. PubMed ID: 24897389
[TBL] [Abstract][Full Text] [Related]
4. Altered expression of ETV1 and its contribution to tumorigenic phenotypes in gastrointestinal stromal tumors.
Zhang Y; Gu ML; Zhou XX; Ma H; Yao HP; Ji F
Oncol Rep; 2014 Sep; 32(3):927-34. PubMed ID: 24970355
[TBL] [Abstract][Full Text] [Related]
5. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
[TBL] [Abstract][Full Text] [Related]
6. ETV1 mRNA is specifically expressed in gastrointestinal stromal tumors.
Jang BG; Lee HE; Kim WH
Virchows Arch; 2015 Oct; 467(4):393-403. PubMed ID: 26243012
[TBL] [Abstract][Full Text] [Related]
7. Low ETV1 mRNA expression is associated with recurrence in gastrointestinal stromal tumors.
Sakamaki K; Funasaka K; Miyahara R; Furukawa K; Yamamura T; Ohno E; Nakamura M; Kawashima H; Hirooka Y; Fujishiro M; Goto H
Sci Rep; 2020 Sep; 10(1):14767. PubMed ID: 32901065
[TBL] [Abstract][Full Text] [Related]
8. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Chi P; Chen Y; Zhang L; Guo X; Wongvipat J; Shamu T; Fletcher JA; Dewell S; Maki RG; Zheng D; Antonescu CR; Allis CD; Sawyers CL
Nature; 2010 Oct; 467(7317):849-53. PubMed ID: 20927104
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.
Ran L; Sirota I; Cao Z; Murphy D; Chen Y; Shukla S; Xie Y; Kaufmann MC; Gao D; Zhu S; Rossi F; Wongvipat J; Taguchi T; Tap WD; Mellinghoff IK; Besmer P; Antonescu CR; Chen Y; Chi P
Cancer Discov; 2015 Mar; 5(3):304-15. PubMed ID: 25572173
[TBL] [Abstract][Full Text] [Related]
10. KIT Exon 11 Codons 557-558 Deletion Mutation Promotes Liver Metastasis Through the CXCL12/CXCR4 Axis in Gastrointestinal Stromal Tumors.
Wang HC; Li TY; Chao YJ; Hou YC; Hsueh YS; Hsu KH; Shan YS
Clin Cancer Res; 2016 Jul; 22(14):3477-87. PubMed ID: 26936919
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.
Haller F; Gunawan B; von Heydebreck A; Schwager S; Schulten HJ; Wolf-Salgó J; Langer C; Ramadori G; Sültmann H; Füzesi L
Clin Cancer Res; 2005 Sep; 11(18):6589-97. PubMed ID: 16166437
[TBL] [Abstract][Full Text] [Related]
12. Heterozygosity loss at 22q and lack of INI1 gene mutation in gastrointestinal stromal tumor.
Yamamoto H; Kohashi K; Tsuneyoshi M; Oda Y
Pathobiology; 2011; 78(3):132-9. PubMed ID: 21613800
[TBL] [Abstract][Full Text] [Related]
13. Targeting ETV1 in gastrointestinal stromal tumors: tripping the circuit breaker in GIST?
Duensing A
Cancer Discov; 2015 Mar; 5(3):231-3. PubMed ID: 25749973
[TBL] [Abstract][Full Text] [Related]
14. Identification of phenothiazine as an ETV1‑targeting agent in gastrointestinal stromal tumors using the Connectivity Map.
Yen CC; Chen LT; Li CF; Chen SC; Chua WY; Lin YC; Yen CH; Chen YC; Yang MH; Chao Y; Fletcher JA
Int J Oncol; 2019 Aug; 55(2):536-546. PubMed ID: 31268158
[TBL] [Abstract][Full Text] [Related]
15. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs.
Martinho O; Gouveia A; Viana-Pereira M; Silva P; Pimenta A; Reis RM; Lopes JM
Histopathology; 2009 Jul; 55(1):53-62. PubMed ID: 19614767
[TBL] [Abstract][Full Text] [Related]
16. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.
Sápi Z; Füle T; Hajdu M; Matolcsy A; Moskovszky L; Márk A; Sebestyén A; Bodoky G
Diagn Mol Pathol; 2011 Mar; 20(1):22-33. PubMed ID: 21326036
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of phosphatidylethanolamine binding protein 1 associates with clinical risk factors in gastrointestinal stromal tumors, but not with activation of the RAF-1-MEK-ETV1 pathway.
Schoppmann SF; Beer A; Nirtl N; Ba-Ssalamah A; Brodowicz T; Streubel B; Birner P
Cancer Lett; 2013 Jul; 335(1):26-30. PubMed ID: 23376254
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
19. High expression of the RNA-binding protein RBPMS2 in gastrointestinal stromal tumors.
Hapkova I; Skarda J; Rouleau C; Thys A; Notarnicola C; Janikova M; Bernex F; Rypka M; Vanderwinden JM; Faure S; Vesely J; de Santa Barbara P
Exp Mol Pathol; 2013 Apr; 94(2):314-21. PubMed ID: 23295309
[TBL] [Abstract][Full Text] [Related]
20. Expression of podoplanin is a rare event in sporadic gastrointestinal stromal tumors and does not influence prognosis.
Schoppmann SF; Berghoff AS; Jesch B; Zacherl J; Nirtl N; Jomrich G; Maroske F; Streubel B; Mesteri I; Birner P
Future Oncol; 2012 Jul; 8(7):859-66. PubMed ID: 22830405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
